

FOR IMMEDIATE RELEASE

Charles Bowman & Company Contact: Anthony Palmieri
Title: Senior Director Global Business Development
P: 616-786-4000
E: cbc@charlesbowman.com

MNL Group Contact: Andres Leschot
Title: R&D Director
E: andres.leschot@mnl-group.com

New Study Confirms MaquiBright® Offers Relief to Eye Dryness And Eye Fatigue Symptoms
MaquiBright® Ingredient Alleviates Symptoms Associated To Dry Eye and Fatigue

Holland, Michigan (May 21, 2019) A new study demonstrates MaquiBright®, a patented formulation of maqui berry extract, relieves symptoms associated with dry eye and eye fatigue. The study, *“Effects of MaquiBright® on Improving Eye Dryness and Fatigue in Humans: A Randomized, Double-blind, Placebo-controlled Trial”* is available online in *The Journal of Traditional and Complementary Medicine* (Yamashita, Suzuki, Yamamoto, Iio, & Yamada, 2018).

The study sponsored by MNL Group and ANKLAM Extract consisted of 74 participants who have eye dryness, eye fatigue and are exposed to more than four hours of visual display terminals (VDT) at work daily. Test subjects took a 60 mg capsule once a day for four weeks and those who had MaquiBright and not the placebo had alleviated eye dryness and showed promising results to the relief with eye fatigue.

“This study demonstrates benefits of dry eye reduction with participants receiving dosage as a supplement,” said Humberto Zuckerman, Vice President Marketing and Sales at MNL Group. “People now have an easier choice to combat dry eye. They can simply take one capsule of MaquiBright a day to complement the usage of eye drops multiple times a day.”



The 2013 US National Health and Wellness Survey showed 16.4 million people in the US suffer from dry eyes symptoms (Farrand, Fridman, Ozer Stillman, & Schaumberg, 2017). The global revenues of manufacturers producing dry eye treatment products is expected to grow from \$4.6 billion in 2018 to \$6.2 billion by 2023 (Downs, 2018). MaquiBright is the only natural oral alternative treatment for dry eye and fatigue symptoms.

“The results of this study solidify the eye health benefits associated with MaquiBright,” said Anthony Palmieri, Sr. Director Global Business Development at Charles Bowman and Company. “Companies looking to expand product lines into the eye health category can rest assured the science matches the benefits.”

About MNL Group

Founded in 2008, MNL Group is a Chilean company dedicated to the research and development of standardized natural extracts for applications within the animal health and nutrition industries. The company produces popular branded ingredients MaquiBright, Delphinol, and MaquiMNL all supported by clinical studies proving efficacy and derived from maqui berries, a superfruit with the highest antioxidant powers known in the world.

Visit www.mnl-group.com for more information.

About Charles Bowman

Founded in 1946, Charles Bowman and Company is a supplier of nutrition ingredients and fine chemicals to the food, feed, pharmaceutical, and health industries. Headquartered in Holland, Michigan, the company has several warehouse facilities across the US to provide exemplary service to customers around the globe. Charles Bowman was named the exclusive US distributor of MaquiBright and other nutritional ingredients produced by MNL Group.

Visit www.CharlesBowman.com or call 616-786-4000 for more information.

###

References

- (n.d.). Retrieved from Coherent Market Insights Global Dry Eye Study, 2018.
- Downs, P. (2018). *2018 Dry Eye Products Report: A Global Market Analysis for 2017 to 2023*. St. Louis: Market Scope.
- Farrand, K. F., Fridman, M., Ozer Stillman, I., & Schaumberg, D. A. (2017, October). *Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older*. Retrieved from American Journal of Ophthalmology:
<https://www.ncbi.nlm.nih.gov/pubmed/28705660>
- Yamashita, S.-i., Suzuki, N., Yamamoto, K., Iio, S.-i., & Yamada, T. (2018, November). *Effects of MaquiBright® on improving eye dryness and fatigue in humans: A randomized, double-blind, placebo-controlled trial*. Retrieved from Journal of Traditional and Complementary Medicine:
<https://doi.org/10.1016/j.jtcme.2018.11.001>